article thumbnail

In gene therapy race, bluebird leads Vertex in activating treatment centers but trails in patient starts

Fierce Pharma

While Vertex leads in patient starts, bluebird has activated more treatment centers. It’s not an easy question to answer.

Leads 316
article thumbnail

Pfizer moves to settle more than 10,000 Zantac cases in state courts: Bloomberg

Fierce Pharma

Following the lead of French pharmaceutical giant Sanofi, Pfizer has agreed to settle more than 10,000 personal-injury claims from users of heartburn drug Zantac, resolving litigation in several U. state courts, according to Bloomberg.

Leads 359
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME

Fierce Pharma

Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising."

Leads 294
article thumbnail

Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

Fierce Pharma

[Yangzhou, China - March 26, 2024] - Aurisco Pharmaceutical, a leading global pharmaceutical company, is excited to announce the completion of its investment in cGMP peptide manufacturing capacity | Aurisco Pharmaceutical Launches State-of-the-Art Manufacturing Facility for GLP-1 Peptides

article thumbnail

The top pharmaceutical companies by R&D expenditure

Pharmaceutical Technology

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

article thumbnail

Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius

Fierce Pharma

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. This marks the third rejection this year for pegcetacoplan in Europe.

article thumbnail

Glenmark recalls 114 batches of low potassium drug in the US over potentially deadly hyperkalemia risk

Fierce Pharma

Glenmark Pharmaceuticals on Tuesday said it’s recalling 114 batches of 750mg potassium chloride extended-release capsules thanks to failed dissolution of the product. That side effect can in turn lead to cardiac arrest.